Protara Therapeutics appoints Patrick Fabbio as CFO effective Jan 30, 2023

Protara Therapeutics, Inc.

Patrick Fabbio appointed CFO, replacing interim CFO Jesse Shefferman (CEO).
Fabbio brings 30+ years life science finance experience; most recently President & CFO of Rafael Holdings.
Compensation: $445k base salary, 45% target bonus, $25k signing bonus, 300k stock option (4-yr vest).
Severance: without cause/good reason → 9 months base + 12 months target bonus + 9 months healthcare.
On change-in-control termination within 12 months: 100% equity acceleration, 12 months base salary.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Patrick Fabbio

Chief Financial Officer

TARA · Protara Therapeutics, Inc.

Effective: 2023-01-30
Filed: January 30, 2023, 6:59 PM ET

On January 30, 2023, Protara Therapeutics, Inc. (the “Company”) announced that, effective as of January 30, 2023, Patrick Fabbio had been appointed as Chief Financial Officer of the Company.

Role change

Jesse Shefferman

Chief Financial Officer

TARA · Protara Therapeutics, Inc.

Effective: 2023-01-30
Successor: Patrick Fabbio
Filed: January 30, 2023, 6:59 PM ET

Mr. Fabbio will serve as the Company’s principal financial officer effective January 30, 2023, replacing Jesse Shefferman, the Company’s President and Chief Executive Officer, who had been serving in such role while the Company searched for a Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Fabbio was appointed as Chief Financial Officer at Protara Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 30, 2023, Protara Therapeutics, Inc. (the “Company”) announced that, effective as of January 30, 2023, Patrick Fabbio had been appointed as Chief Financial Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Jesse Shefferman changed role as Chief Financial Officer at Protara Therapeutics, Inc..

Action: replaced
Role: Chief Financial Officer

Exact text from the filing

Mr. Fabbio will serve as the Company’s principal financial officer effective January 30, 2023, replacing Jesse Shefferman, the Company’s President and Chief Executive Officer, who had been serving in such role while the Company searched for a Chief Financial Officer.

View on SEC.gov

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-005811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.